Talaris Therapeutics to Participate at Two Upcoming Investor Conferences

BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today announced that members of its senior management team will participate at the following investor conferences: Morgan Stanley Healthcare Corporate Access DayDate: Tuesday, March 29, 2022Location: Boston Harbor Hotel, Boston, MA1x1 meetings only Guggenheim Virtual Genomic Medicines and Rare Disease DayFireside chat date: Thursday, March 31, 2022Fireside chat time: 3:00 p.m. ET A live webcast of the presentation at the Guggenheim Genomic Medicines and Rare Disease Day will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, a replay of the event can be found on the Talaris website. About Talaris TherapeuticsTalaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX. Media ContactLisa RaffenspergerTen Bridge [email protected] (617) 903-8783 Investor ContactChris BrinzeyICR [email protected] (339) 970-2843